Follow Us
About Cytovale
Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Cytovale’s FDA-cleared IntelliSep test is pioneering a new way of quickly and accurately analyzing white blood cells (WBCs) to stratify a patient’s risk of sepsis from a standard blood draw in ~8 minutes. The IntelliSep test categorizes patients into three bands according to their probability of sepsis.
The results may equip providers with a tool to optimize clinical outcomes and empower hospitals to improve resource utilization and achieve operational excellence. IntelliSep may also support hospital efforts to meet guidelines set by the Centers for Medicare & Medicaid Services (CMS) for timely sepsis treatment, known as SEP-1.
Made up of an extraordinary team of life scientists, engineers, clinicians, and dreamers, Cytovale intends to accelerate the time it takes to get from triage to life-saving therapies.
For more information, please visit our website: www.cytovale.com
If you would like to learn more or have any questions, please reach out to us at: info@cytovale.com
Real-World Impact of the IntelliSep Sepsis Test
According to a recently presented study, a site that used the IntelliSep sepsis test as part of their ED sepsis protocol has realized improved patient care, reduced length of stay by an average of 1.28 days and $1,429 cost savings on average per patient tested with IntelliSep.
IntelliSep Patient Experience
IntelliSep Real World Impact: One Site's Early Results
IntelliSep Intended Use: To aid in the early detection of sepsis with organ dysfunction manifesting within the first 3 days after testing, in conjunction with clinical assessments and laboratory findings. IntelliSep is indicated for use in the Emergency Department (ED) for adult patients that present with signs and symptoms of infection.
Cytovale Team
There are no matching speakers.